The company anticipates the enrolment of approximately 1,000 patients to evaluate population-based prophylaxis in contacts of SARS-CoV-2 infected patients. The post-exposure prophylaxis clinical trial will evaluate the preventive effect and safety of CT-P59 and whether CT-P59 can elicit a neutralising antibody response to prevent the virus from infecting human cells.
"We hope anti-COVID-19 monoclonal antibodies such as CT-P59 can provide high-risk individuals with effective protection against COVID-19 and help prevent further spread in the community," said Dr
Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers…
According to the company, CT-P59 has previously shown promising safety results in its Phase I clinical trial in healthy volunteers. The MFDS has now approved
The post Celltrion COVID-19 antibody treatment to enter Phase III trial appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2020. All Rights Reserved., source